conoscenti di NicOx che siglano accordi
Ortho-McNeil-Janssen Pharmaceuticals, Inc.
and
Janssen Pharmaceutica NV
(collectively “OMJ”)
ovvero => J&J
Press releases - Orexo
Orexo enters into an alliance and license agreement for new drugs to treat respiratory diseases
Uppsala, Sweden, June 1 2010 - Orexo (OMX: ORX) has entered a research and development alliance and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (collectively “OMJ”). The licenses granted to OMJ under the agreement include worldwide licenses to Orexo’s ongoing OX-CLI and OX-ESI programs focusing on discovering and developing innovative small-molecule treatments for asthma, chronic obstructive pulmonary disease, and other inflammatory diseases. In addition, OMJ will add a third internal program focusing on discovering and developing innovative small-molecules against an undisclosed target to the alliance on the same financial terms.
Initially, the agreement will run for three years, with an option for OMJ to extend the alliance and funding.
To Orexo, the alliance will bring a research funding contribution of up to USD 21.5 million (SEK 167 million) over the first three years, including an upfront payment of USD 10 million (SEK 77.8 million).
Upon the successful development and commercialization of all three initial alliance programs for multiple indications, Orexo will be entitled to total development milestone payments of up to USD 564 million (SEK 4,390 million), plus additional sales milestones for each program. Commercialized products will also provide royalties.
In addition, the agreement grants Orexo an option for rights to co-promote drugs from the programs marketed by OMJ in Nordic and Baltic countries.
OMJ will be responsible for all clinical development and commercialization activities, including costs.
The alliance will leverage Orexo’s world-leading expertise in the arachidonic acid field and its two advanced pre-clinical programs aimed at developing powerful new drugs in the fight against serious respiratory illnesses.
Torbjörn Bjerke, President and CEO of Orexo, said:
“I am delighted to announce this exciting alliance with OMJ in the area of new drug discovery and development. There are significant medical needs in the fields of respiratory and inflammatory diseases. We believe that our research and development is of the highest international standards. We look forward to further demonstrating our capabilities through this alliance. By combining our skills and resources in this area, we look to discover and develop potential new drugs for millions of patients. This agreement adds to the other good alliances we have made and is an important element for Orexo in becoming a profitable pharmaceutical company.”
In accordance with international financial reporting and accounting standards, the revenues from the upfront payment of USD 10 million will be recognised in the company’s profit & loss account evenly over a 36-month period.
Reuters - 02/06/2010 10:42:20
